US · Healthcare · Biotechnology
EPS came in at -0.20 against a street estimate of -0.10 — a miss of 100.0%.
Analysts rate Gossamer Bio Inc a buy (4 buy, 3 hold, 1 sell out of 8) with an average price target of $95.40.
| Fund | Stake |
|---|---|
| D. E. Shaw & Co LP | 8.37% |
| DeepCurrents Investment Group LLC | 7.70% |
| Context Capital Management LLC | 5.92% |
| Worth Venture Partners, LLC | 5.11% |
| Kalehua Capital Management LLC | 4.56% |
| AQR Capital Management LLC | 3.19% |
| GSA Capital Partners LLP | 3.06% |
| Wolverine Asset Management LLC | 2.64% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gossamer Bio Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.